Pfizer's Inlyta, BI/Lilly's Jentadueto, Vertex' Kalydeco & NovoThirteen get CHMP nods
This article was originally published in Scrip
Executive Summary
Medicines featuring on the European Medicines Agency's list of positive opinions from the May meeting of the Committee for Medicinal Products for Human Use (CHMP) included Pfizer's oral tyrosine kinase inhibitor Inlyta (axitinib) and Boehringer Ingelheim/Lilly's combination diabetes product Jentadueto (linagliptin plus metformin). Two drugs for rare diseases, Vertex Pharmaceuticals' Kalydeco (ivacaftor) and Novo Nordisk's NovoThirteen (catridecacog) were also accorded positive opinions.